Pharmaceuticals

Promising clinical trial results show a new inhaler delivers nicotine as fast as a cigarette, offering a breakthrough for smoking cessation after decades of failure.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

Aardvark Therapeutics is expanding its Phase 3 trial for a novel Prader-Willi Syndrome drug to include children as young as seven, targeting a key unmet need.

A new partnership between South Korea's GCCL and Europe's Medicover MICS promises to streamline drug development by creating a seamless East-West axis.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

APhA awards honor the growing role of pharmacists in national immunization, highlighting innovation, dedication, and the future of community healthcare.

AB Science's Masivet gets key FDA designation, paving the way for a new targeted cancer therapy for dogs and a major strategic win for the company.

Carterra's new 48-channel Vega platform delivers a 12-fold leap in throughput, promising to reshape primary drug screening and feed AI pharma models.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A Chinese biotech's novel nasal spray flu vaccine enters trials. Its unique design could finally make it safe for the elderly and expand global access.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

With a new flexible, founder-first model, Activation Capital's Frontier BioHealth program aims to bridge the commercialization gap for life sciences startups.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Bruker divisions unveil an open, AI-driven platform at SLAS2026, aiming to unify fragmented labs and enable 24/7 autonomous scientific discovery.